Frontier Biotechnologies Gestione

Gestione criteri di controllo 3/4

Frontier Biotechnologies Il CEO è C. J. Wang, nominato in Jan2013, ha un mandato di 11.83 anni. possiede direttamente 5.62% delle azioni della società, per un valore di CN¥ 156.47M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 10.3 anni e 6.5 anni.

Informazioni chiave

C. J. Wang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11.8yrs
Proprietà del CEO	5.6%
Durata media del management	10.3yrs
Durata media del Consiglio di amministrazione	6.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

C. J. Wang (66 yo)

11.8yrs

Mandato

CN¥2,228,000

Compensazione

Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Qi Shao	Senior VP & CFO	8.8yrs	CN¥1.37m	Nessun dato
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	no data	CN¥593.80k	Nessun dato
Hangzhou Lv	Senior Vice President of Marketing & Sales	no data	CN¥1.22m	Nessun dato
Qianya Gao	Deputy GM & Secretary of the Board of Directors	3.9yrs	CN¥962.00k	Nessun dato
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Xiao Zheng	Chief Operating Officer	3.7yrs	CN¥3.47m	Nessun dato
Michael Hu	C.M.O.	no data	Nessun dato	Nessun dato

10.3yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 688221 è esperto e expertise (durata media dell'incarico 10.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	5.8yrs	CN¥593.80k	Nessun dato
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Chi Kit Ng	Independent Director	5.8yrs	CN¥150.00k	Nessun dato
Yuantao Cao	Supervisor	6.5yrs	Nessun dato	Nessun dato
Guangji Wang	Independent Director	2.5yrs	CN¥130.20k	Nessun dato
Kai Chen	Independent Director	5.8yrs	CN¥90.70k	Nessun dato
Zhi Zhong Jiang	Chairman of the Supervisory Board & Purchasing Director	8.8yrs	CN¥380.60k	Nessun dato

6.5yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 688221 sono considerati esperti (durata media dell'incarico 6.5 anni).

Frontier Biotechnologies Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media